-
Iranian in possible France prisoner swap jailed for a year
-
US, Ukraine hold talks in Geneva as Russia says 'no deadlines' to end war
-
English giants dominate line-up for Champions League last-16 draw
-
Iran, US hold talks in push to avert war
-
South Africa thrash West Indies in T20 World Cup statement win
-
ECB books third straight annual loss
-
Injury forces Marquez to adapt for MotoGP opener
-
Booming markets propel Hong Kong exchange's profits to record high
-
West Indies recover from 83-7 to post to 176-8 against South Africa
-
Filmmakers defend Berlin festival chief in Gaza row
-
Hong Kong mogul Jimmy Lai wins appeal in fraud case
-
Iranian in possible prisoner exchange faces 'terrorism' verdict in France
-
'Street-smart' New Zealand can topple England to make T20 semis: coach
-
Iran-US talks begin in push to avert war
-
Merz says Germany, China must overcome trade gaps 'together'
-
Automaker Stellantis posts massive loss, pivots from EV
-
US, Ukraine to meet in Geneva after overnight Russian strikes
-
Snake-like robot unveiled for Fukushima debris removal
-
'Public lynching': Senegal cracks down on LGBTQ+ community
-
Hong Kong sentences father of wanted activist to 8 months in jail
-
The woman fighting to reclaim her face from Albania's 'AI minister'
-
Bulgaria ski station becomes refuge for digital nomads
-
Thai runner-up party seeks criminal case against election officials
-
North Korea's Kim shuns South but could 'get along' with US
-
Spurs win 10th straight, Pistons silence Thunder in battle of NBA's best
-
Germany's Merz visits China AI hub hoping for business deals
-
Post-uprising polls won't shake Nepal's delicate India-China balance
-
S.Korea's Park Chan-wook to head Cannes festival jury
-
Australian ex-PM says 'more important than ever' to ditch UK monarchy
-
Dressed for succession? Kim Jong Un, daughter fuel speculation with matching coats
-
US-Ukraine talks to open in Geneva after overnight Russian strikes
-
Export ban sparks rush to process lithium in Zimbabwe
-
Pakistani sculptor turns scrap into colossal metal artworks
-
Epstein files reveal links to cash, women, power in Africa
-
Where are Southeast Asia's data centres?
-
Where AI lives: Southeast Asia's data centre boom
-
Seoul hits fresh record on mixed day for Asia markets
-
Kyiv residents pool together for solar panels and batteries amid Russian strikes
-
North Korea's Kim says could 'get along' with US but shuns South
-
Cuba kills four on US-registered speedboat trying to 'infiltrate'
-
UK Labour party threatened by hard-right, leftists in heartland
-
Australian PM sorry after saying sexual assault survivor 'difficult'
-
Kim Jong Un spurns olive branch from 'hostile' South Korea
-
DR Congo sanctuary resists bloody forest sell-off
-
North Korea looking to replicate youth success at Women's Asian Cup
-
Deal or no deal: What's the state of Trump's tariffs?
-
Hillary Clinton to testify in US House panel's Epstein probe
-
African migrants won legal protections - then Trump deported them
-
US women's ice hockey captain responds to 'distasteful' Trump remark
-
US presses missile issue as new Iran talks to open in Geneva
Water Tower Research Highlights Ainos' SmellTech Platform AI Nose as Foundational AI Innovation
AI Nose delivers accuracy and versatility, driving scalable growth across healthcare, industrial and robotics markets
Technology, data moat, and strategic partnerships position Ainos for accelerated commercial readiness and expansion
SAN DIEGO, CALIFORNIA / ACCESS Newswire / July 24, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a leader in AI-powered scent digitization, today announced that Water Tower Research has published a recap of its recent Small-Cap Spotlight podcast. The report highlights the Company's AI Nose platform, an advanced smell digitization technology powered by artificial intelligence and built on over a decade of innovation, a deep data moat, strategic partnerships, and a clear commercialization roadmap. The report identifies AI Nose as a foundational innovation in olfactory AI, a rapidly emerging and underdeveloped frontier within the sensory AI landscape.
Key Highlights from the Report:
AI Nose establishes olfactory AI as a powerful new tool for industrial intelligence, combining accuracy with adaptability: AI Nose delivers 90+% accuracy in distinguishing everyday scents, 85% in senior care environments, and 80% across 22 industrial scent types in semiconductor settings. Its AI model, smell language model (SLM), improves with each use, creating a powerful data-driven flywheel effect that can support scalable deployment across multiple high-growth verticals.
Early-mover innovation and data moat cement AI Nose's distinct competitive edge in smell digitization: While most AI innovation has focused on vision and voice, Ainos positions smell as a high-impact, underdeveloped frontier. Built on over a decade of technical innovation and a growing scent dataset, AI Nose combines advanced calibration, high-precision signal processing, and custom sensor arrays into a powerful scent sensing platform. Originally developed for medical use, the platform has expanded into robotics, semiconductor manufacturing, and industrial automation, positioning it as a frontrunner in the fast-emerging field of olfactory AI.
Strategic partnerships fuel commercial scale-up across key verticals: Ainos is rapidly expanding AI Nose's market reach and accelerating commercialization through strategic alliances - with more likely to come. The Company sees Asia as a key launchpad given the region's strengths in electronic manufacturing services, semiconductors, automation and robotics. At the same time, Ainos welcomes partnership opportunities in the U.S. and Europe to support global commercialization.
Read the Full Water Tower Research Report Here: https://www.watertowerresearch.com/doc?docID=UR_AIMD_07202025
Those interested can listen to the full podcast via Apple Podcasts, Spotify, or Water Tower Research's website.
About AI Nose
AI Nose digitizes scent into Smell ID, an AI-driven scent intelligence. This full-stack electronic nose (e-nose) platform combines precision MEMS sensor arrays with proprietary AI algorithms, aiming to detect scent at parts-per-billion (ppb) sensitivity. Smell ID then converts analog scent data into actionable insights, while the proprietary smell language model (SLM) learns complex scent patterns. Backed by a 13-year scent data moat and deep medtech expertise, AI Nose aims to deliver continuous monitoring, predictive analytics, and instant alerts to boost safety, quality, and efficiency. To be delivered as SmellTech-as-a-Service, it aims to offer subscription access to ongoing scent intelligence, analytics, and real-time alerts, turning the invisible into strategic advantage.
About Ainos, Inc.
Ainos, Inc. (NASDAQ: AIMD) is a dual-platform AI and biotech company pioneering smelltech and immune therapeutics. Its AI Nose platform and smell language model (SLM) digitize scent into Smell ID, a machine-readable data format, powering intelligent sensing across robotics, smart factories, and healthcare. The company also develops VELDONA®, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases. Ainos, a fusion of "AI" and "Nose," is redefining machine perception for the sensory age. To learn more, visit https://www.ainos.com. Follow Ainos on X, formerly known as Twitter, (@AinosInc) and LinkedIn to stay up-to-date.
Forward-Looking Statements
Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company's business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated by the forward-looking statements in this press release. These factors include, among other things, our expectation that we will incur net losses for the foreseeable future; our ability to become profitable; our ability to raise additional capital to continue our product development; our ability to accurately predict our future operating results; our ability to advance our current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize any product candidates we develop; the ability to obtain and maintain regulatory approval of our product candidates; delays in completing the development and commercialization of our current and future product candidates; developing and commercializing additional products, including diagnostic testing devices; our ability to compete in the marketplace; compliance with applicable laws, regulations and tariffs, and factors described in the Risk Factors section of our public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this press release and, except to the extent required by applicable law, the Company undertakes no obligation to update or revise these statements, whether as a result of any new information, future events and developments or otherwise.
Contact Information
Feifei Shen
[email protected]
SOURCE: Ainos, Inc.
View the original press release on ACCESS Newswire
A.Mahlangu--AMWN